625-mg FC tab: RANCLAV is indicated for the treatment of following infections caused by susceptible pathogens: Lower respiratory tract infections (e.g.pneumonia, bronchitis); Acute otitis media.
Urinary tract infections.
Skin and soft tissue infections.
1-g FC tab: RANCLAV tablets are indicated for the treatment of following infections by susceptible pathogens: Upper respiratory tract infections (including otorhinolaryngeal) e.g. sinusitis, otitis media, tonsillitis.
Lower respiratory tract infections (e.g. lobar and bronchopneumonia, acute and chronic bronchitis).
Genito-urinary tract infections (e.g. cystitis, urethritis, pyelonephritis).
Skin and soft tissue infections (e.g. boils, abscesses, cellulitis, wound infections).
Bone and joint infections (e.g. osteomyelitis).
Dental infections (e.g. dentoalveolar abscess).
Other infections (e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis).
Susp: Ranclav 228.5 & 457 Suspension is indicated for the short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as a cause. In other situations, amoxicillin alone should be considered.
Upper respiratory tract infections (including ENT) in particular sinusitis, otitis media, recurrent tonsillitis. These infections are often caused by Streptococcus pneumoniae, Haemophilus influenzae*, Moraxella catarrhalis* and Streptococcus pyogenes.
Lower respiratory tract infections in particular acute exacerbations of chronic bronchitis (especially if considered severe), lobar and bronchopneumonia. These indications are often caused by Streptococcus pneumoniae, Haemophilus influenzae* and Moraxella catarrhalis*.
Urinary tract infections in particular cystitis (especially when recurrent or complicated excluding prostatitis). These infections are often caused by Enterobacteriaceae* (mainly Escherichia coli*), Staphylococcus saprophyticus, Enterococcus species*.